Home Blog Page 2498

Erayak Power Solution Announces Receipt of Nasdaq Delisting Notice Subject to Hearing Request

By
Advertorial Desk
-

WENZHOU, China, Sept. 9, 2025 /PRNewswire/ — Erayak Power Solution Group Inc. (Nasdaq: RAYA), a leading manufacturer, designer, and exporter of high-quality products in the power supply industry, today announced it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) on September 3, 2025, notifying that the Company is not in compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”), as the Company’s securities had a closing bid price of $0.10 or less for the last ten consecutive trading days. The letter indicated that, as a result, the Nasdaq staff determined to delist the Company’s securities from The Nasdaq Global Market (the “Delisting Determination”).

The letter also indicated that the bid price of the Company’s Class A ordinary shares had closed at less than $1 per share over the previous 30 consecutive business days, and as a result, the Company is not in compliance with Listing Rule 5450(a)(1) (the “Rule”). Normally, a company is provided 180 calendar days to regain compliance with the Rule in accordance with Listing Rule 5810(c)(3)(A). However, the Nasdaq determined that the Company’s securities also had a closing bid price of $0.10 or less for the last ten consecutive trading days. Accordingly, the Company became subject to the provisions contemplated under the Low Priced Stocks Rule. As a result, the Nasdaq determined to delist the Company’s securities from The Nasdaq Capital Market. The Company was provided until September 10, 2025 to request an appeal of the Delisting Determination to the Hearings Panel (the “Panel”). If the Company fails to request an appeal by September 10, 2025, trading of the Company’s securities will be suspended at the opening of business on September 12, 2025, and a Form 25-NSE will be filed with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market.

The Company intends to request such hearing to appeal the Delisting Determination before September 10, 2025, which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision.

The Company is considering all potential options available to it to regain compliance with the aforementioned rules, including seeking shareholders’ approval for a reverse stock split.

About Erayak Power Solution Group Inc.

Erayak specializes in the manufacturing, research and development, and wholesale and retail of power solution products. Erayak’s product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery and smart chargers, and custom-designed products. Our products are used principally in agricultural and industrial vehicles, recreational vehicles, electrical appliances, and outdoor living products. Our goal is to be the premier power solutions brand and a solution for mobile life and outdoor living. For more information, visit www.erayakpower.com. 

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Email: investor@erayakpower.com 

Maxx Upgrades Affordable SIM-Only Plan with 5G

By
Advertorial Desk
-

SINGAPORE, Sept. 9, 2025 /PRNewswire/ — M1’s Maxx provides some of Singapore’s most affordable SIM-Only plans, now with 5G connectivity for all new and existing customers. As part of a limited-time offer, this upgrade is available at no cost to all customers.

Why Maxx SIM-Only Plans Have Been Upgraded to 5G

The new 5G SIM upgrade is part of Maxx‘s commitment to providing a seamless data experience that is both affordable and accessible to a wider audience. According to M1’s Media Alert, the Maxx network is “Powered by M1’s ultra-fast 5G network, consistently ranked among the best in Singapore“, and “delivers a high-performance mobile experience wherever you are.”

Maxx SIM-Only Plans Eligible for 5G Upgrade

M1 states that “Maxx plans are built for customers who want simplicity, flexibility and great value”, which is why the free 5G upgrade is available to all Maxx SIM-Only plans S$10 and above. The S$10 Maxx 5G SIM-Only Plan comes with:

  • 400GB Local Data in Singapore and Malaysia
  • 16GB Roaming Data (13GB for APAC, 3GB for International)
  • Up to 300 IDD Minutes
  • 500 minutes of talktime for local outgoing calls
  • Unlimited local incoming calls
  • 50 local SMS

How to Upgrade a Maxx SIM-Only Plan to 5G

Customers can check their handset, SIM, and plan eligibility by navigating to “Account” and then “Check Your 5G Readiness” within the Maxx App.

Existing customers can upgrade their Maxx SIM to 5G via two methods:

  • Maxx App: Customers who prefer a 5G eSIM can upgrade instantly by logging into their Maxx App and tapping on: Account > SIM Management > Upgrade to 5G eSIM
  • In-Person: Customers can visit designated M1 Shops or SIM exchange roadshows to get a physical 5G SIM for their phone. Users who would like to visit a roadshow for a physical 5G SIM can visit the following link for a list of roadshow locations.

As a trusted choice for mobile users across Singapore, Maxx looks forward to delivering a speedy and reliable mobile experience for its customers with the 5G upgrade for its affordable SIM-Only plans.

About M1

M1, a subsidiary of Keppel Ltd., is Singapore’s first digital network operator, providing a suite of communications services, including mobile, fixed line and fibre offerings, to over two million customers.

Since the launch of its commercial services in 1997, M1 has achieved many firsts – becoming one of the first operators to be awarded one of Singapore’s two nationwide 5GSA standalone network licences, first operator to offer nationwide 4G service, as well as ultra high-speed fixed broadband, fixed voice and other services on the Next Generation Nationwide Broadband Network (NGNBN).

M1’s mission is to drive transformation and evolution in Singapore’s telecommunications landscape through cutting-edge technology and made-to-measure offerings. For more information, visit m1.com.sg

KuCoin Pay Launches On-Chain Payment Solution for Merchants and Consumers, Advancing Responsible Innovation to Enhance Crypto Accessibility for All

By
Advertorial Desk
-

PROVIDENCIALES, Turks and Caicos Islands, Sept. 9, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency exchange, today announced that its crypto payment arm, KuCoin Pay, has introduced its On-Chain Payment Solution. This empowers merchants and consumers with a decentralized framework for direct cryptocurrency payments on the blockchain. By leveraging a comprehensive AML compliance system, it enables seamless wallet-to-wallet transactions without intermediaries and delivering the inherent speed, security, and transparency of decentralized systems.


Backed by KuCoin’s regulated and reliable ecosystem, the solution revolutionizes crypto commerce. It offers seamless on-chain payments through direct wallet-to-wallet transfers, enabling instant settlements. With multi-chain support, KuCoin Pay is compatible with major blockchains and accommodates preferred assets such as BTC, USDT, USDC, and more. Users benefit from low-cost structures, paying only gas fees, while merchants enjoy seamless access to the global market along with easy-to-integrate APIs and payout functionality.

Designed for adoption by small- and medium-sized merchants—from e-commerce sites to physical retail—the On-Chain Payment Solution features turnkey white-label integration. This allows businesses to launch customized crypto payment systems without developing infrastructure from scratch, preserving brand identity while simplifying onboarding, reducing technical complexity, and accelerating time to market. For merchants, the solution reduces fraud and chargeback risks through irreversible transactions, unlocks access to a fast-growing crypto user base, and creates opportunities for innovative business models. By offering modern payment options, merchants can strengthen customer loyalty while positioning themselves at the forefront of the Web3 and DeFi movement. The white-label advantages deliver a competitive edge over traditional providers. For users, the solution delivers seamless checkout experiences with direct crypto payments, empowering them with greater control over funds. They can choose from a wide range of assets, including BTC, ETH, and stablecoins, and enjoy borderless accessibility wherever they are in the world.

“This On-Chain Payment Solution marks a pivotal advancement in bridging cryptocurrency with everyday commerce. With its turnkey white-label capabilities, it empowers merchants to integrate crypto payments effortlessly while maintaining brand integrity,” said Raymond Ngai, KuCoin Pay Lead. “By prioritizing direct, secure, and cost-effective transactions, we’re not only enhancing trust and efficiency but also driving responsible innovation to make crypto accessible for all.”

About KuCoin Pay

KuCoin Pay is a pioneering merchant payment solution that enables businesses to integrate cryptocurrency transactions for both online and offline sales. Supporting over 50 cryptocurrencies including KCS, USDT, USDC, and BTC, KuCoin Pay delivers fast, secure, and borderless payments to its audience.

Xinhua Silk Road: 8th Shenyang International Open Regatta held in NE. China’s Shenyang

By
Advertorial Desk
-

BEIJING, Sept. 9, 2025 /PRNewswire/ — The 8th Shenyang International Open Regatta took place from September 5 to 7 in Shenyang, capital of northeast China’s Liaoning Province.

A total of 306 athletes from 31 domestic and international rowing teams competed on the Hunhe River, which is acclaimed as one of China’s most beautiful urban still water rowing courses.

The university category of this year’s regatta featured teams from renowned Chinese universities such as Peking University and Liaoning University, as well as international entrants including New Zealand’s University of Otago, Korea University of the Republic of Korea, and Universiti Tun Hussein Onn Malaysia. Other categories included the club, the youth, and the entrepreneur groups.

Jointly hosted by Shenyang Municipal People’s Government, Shenyang sports bureau and Shenyang Qingquan Shengjing culture and sports development Co., Ltd, the event aims to solidify its status as China’s premier rowing competition, craft high-quality urban cultural brand, and facilitate the city’s development into an internationally renowned “rowing capital”.

Original link: https://en.imsilkroad.com/p/347458.html

Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC

By
Advertorial Desk
-

SHANGHAI, Sept. 9, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leading assets, ZEGFROVY® (sunvozertinib) and golidocitinib, in non-small cell lung cancer (NSCLC) at the 2025 World Conference on Lung Cancer (WCLC), held September 6–9 in Barcelona, Spain.

ZEGFROVY: Targeting EGFR exon20ins and a wide spectrum of EGFR mutations

The latest data from the multinational pivotal WU-KONG1 Part B (WU-KONG1B) study for ZEGFROVY were presented in an oral session at the conference and simultaneously published in the Journal of Clinical Oncology. Based on results from WU-KONG1B, ZEGFROVY received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2025 as the only targeted oral therapy for NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).

ZEGFROVY demonstrated a favorable benefit/risk profile in patients with platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The study showed robust and durable antitumor activity with a manageable safety profile. (#MA08.01).

In addition to the oral presentation, multiple studies of ZEGFROVY were presented at the WCLC, highlighting its potential across a broad range of NSCLC patients, including those with EGFR exon20ins across all lines of therapy, uncommon EGFR and HER2 mutations, EGFR-sensitive mutation and co-mutations, and EGFR mutations resistant to EGFR TKIs. Both monotherapy and combination regimens were evaluated.

In EGFR exon20ins NSCLC, ZEGFROVY demonstrated promising antitumor efficacy and a tolerable safety profile across first- and second- line, as well as adjuvant and neoadjuvant treatment settings.

  • ZEGFROVY combined with anlotinib achieved an objective response rate (ORR) of over 80% and a disease control rate (DCR) of 100% in treatment-naïve EGFR exon20ins NSCLC (#P3.12.43).
  • In previously treated patients, ZEGFROVY combined with bevacizumab achieved a DCR of 100%, with target tumor lesion shrinkage observed in 85.7% of patients. With a median follow-up of 15.2 months, the median duration of response (DoR) was 19.1 months, and three patients (3/14) remained in response at the data cut-off (#P2.10.13).

Real-world cases supported the potential of ZEGFROVY in early- and advanced- stage NSCLC patients with EGFR exon20ins.

  • As a neoadjuvant therapy, ZEGFROVY showed encouraging clinical benefit, with all 3 patients achieving an obvious partial response (PR) before surgery. (#EP.07.49).
  • In the adjuvant setting, ZEGFROVY showed sustained efficacy and tolerable safety profiles, helping patients successfully pass the 1-year after surgery, a peak period for disease recurrence (#EP.07.55).
  • In the first-line maintenance setting, ZEGFROVY showed sustained efficacy and safety in lung adenocarcinoma patients who were intolerant to immunotherapy and chemotherapy (#EP.12.47).

In NSCLC patients harboring uncommon EGFR mutations, ZEGFROVY combined with anlotinib demonstrated promising efficacy, including one patient who achieved complete remission of intracranial lesions (#P3.12.43). In a separate real-world case series, ZEGFROVY exhibited clinical efficacy in advanced NSCLC with HER2 exon20ins, with tumor shrinkage obviously observed post-prior treatment failures (#EP.12.46).

In treatment-naïve NSCLC patients with EGFR-sensitive mutation and co-mutations, ZEGFROVY in combination with anlotinib achieved an ORR of 77.8% and a DCR of 100% (#P3.12.22). In NSCLC patients with EGFR mutations who failed prior EGFR-TKI therapies, ZEGFROVY, both as monotherapy (#EP.12.43) and in combination with chemotherapy (#P3.12.47), was well tolerated and demonstrated encouraging antitumor activity.

Golidocitinib: Janus kinase 1 (JAK1) only inhibitor Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC

Resistance to first-line immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) leads to limited treatment options and poor prognosis. Preclinical and early clinical data have shown synergistic effects between JAK inhibitors and anti-PD-1, suggesting a promising therapeutic strategy in this population. Golidocitinib in combination with anti-PD-1 was being evaluated in immune-resistant NSCLC patients. The study showed a well-tolerated profile, with no DLTs observed in the dose-escalation phase. Ongoing enrollment and data collection will provide deeper insights into clinical utility of golidocitinib (#P1.11.74).

Dr. Xiaolin Zhang, CEO of Dizal, remarked, “Dizal is advancing therapies for patients with NSCLC across EGFR exon 20 insertion, uncommon and EGFR-sensitizing mutations to address significant unmet medical needs. Through scientific innovation, we aim to deliver safe, effective and transformative treatments to patients worldwide.”

–      End    –

About ZEGFROVY®(sunvozertinib)

ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The China approval is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.

In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins.

ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.

WU-KONG28, a phase III, multinational, randomized study assessing ZEGFROVY as a first-line treatment for patients with EGFR exon20ins NSCLC, has completed enrollment across 16 countries and regions.

Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.

About golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com

Business Development: bd@dizalpharma.com

Media Contact: pr@dizalpharma.com

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

By
Advertorial Desk
-
  • End-to-end Green CRDMO solutions to enable global clients for broader positive impact
  • Span from biologics research, development, manufacturing, and overall operations
  • Integration with lean management and digitalization for continuous excellence
  • A comprehensive ecosystem featuring diverse energy-saving and carbon-reduction initiatives

SHANGHAI, Sept. 9, 2025 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently launched the “WuXi Biologics Green CRDMO White Paper” at its first CRDMO+ Open Day event, sharing the end-to-end Green CRDMO solution for biologics and driving the sustainable development of the global biologics industry supply chain. Last November, the company’s Green CRDMO solution was also featured in the “20 Case Examples for 20 Years” report initiated by the United Nations Global Compact, making it the only case in the pharmaceutical industry to receive this honor.

Along with an overall introduction to the company’s strategic approach toward sustainability and climate change, the White Paper details WuXi Biologics’ green innovation technologies across the research, development and manufacturing of biologics, and showcases the significant carbon reduction achieved through green operations. A total of 242 energy-saving cases are compiled in the White Paper, spanning five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories within the industry.

In addition, the paper highlights how the integration of lean management and digitalization with sustainability enhances resource and energy efficiency, while driving continuous improvement. In 2024, over 90% of the company’s completed Kaizen projects achieved ESG benefits, including reductions in carbon emission, water consumption and waste generation.

With a deep understanding of the importance of tackling climate change, WuXi Biologics has adopted a comprehensive, integrated strategy with measurable targets and a well-defined roadmap. Recently, the company announced a new target matrix approved by SBTi, an acknowledgement that further inspires its steadfast dedication to leading the way to a net-zero economy.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are pleased to release the Green CRDMO White Paper with the aspiration that our insights and best practices will inspire and empower the whole industry to drive sustainable progress. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to deliver meaningful and far-reaching impacts.”

As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security “A List” and Supplier Engagement Assessment “A List”, and awarded a CDP Climate Change leadership-level “A-” score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain. 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

Changan Debuts at IAA Mobility 2025, Showcasing a New Vision for Global Smart Mobility

By
Advertorial Desk
-

MUNICH, GERMANY – Media OutReach Newswire – 9 September 2025 – On ‌September 8‌, Changan unveiled its latest advancements in electrification and intelligent technology at ‌IAA Mobility 2025‌. The showcase featured models from ‌CHANGAN DEEPAL and ‌AVATR ‌under the theme “Technological Value, Global Mobility, User Empathy”‌.

Changan Debuts at IAA Mobility 2025

In pursuit of its vision to become a world-class auto brand, Changan has invested ‌over 110 billion RMB in new energy and intelligent technologies over the past decade. With a ‌global network‌ spanning ten R&D centers in six countries, the company has achieved breakthroughs in more than 400 key EV technologies‌ and independently developed ‌its SDA‌ platform. The exhibits – including the ‌Golden Shield Battery and SDA Pilot‌ – highlighted its forward-looking technological achievements.

Changan is accelerating its “Global Mobility” strategy through global partnerships. Its overseas operations now span five regions, namely Europe, Eurasia, Southeast Asia, Middle East and Africa, and Central & South America, covering 103 countries and regions. The company plans to establish 20 overseas factories, nine of which are already operational, including its inaugural overseas NEV plant in Rayong, Thailand. It also continues to advance its plans for local manufacturing in Europe, reinforcing its commitment to regional production and supply chain integration.

Changan is expanding its sales and service presence in Europe. Autohaus Guenther, near Hamburg, opened the first Changan showroom in Germany in late August. Meanwhile, the UK will see ‌20 dealerships begin operations by mid-September, with ‌30 additional sales and service outlets‌ scheduled to launch by the end of 2025. By year-end, Changan will be present in more than 10 European markets, including Spain and Italy. The company has also established import subsidiaries‌ in Germany, the Netherlands, and the UK. Notably, Bosch and ZF, two of the world’s leading manufacturers of automotive components, showcased their joint work with Changan on electrification and automation at IAA Mobility 2025.

Changan remains committed to addressing user needs, earning global recognition through its empathetic, user-centered philosophy. The E-SUV CHANGAN DEEPAL S05‌, launched at IAA Mobility 2025, embodies its philosophy of ‌”European Design, Global Innovation.” Meanwhile, AVATR emphasizes originality and intelligent new luxury, with the globally premiered concept car, Xpectra, showcasing a distinctive design philosophy and advanced technologies.

Changan made history as ‌the only Chinese automaker‌ to exhibit at the IAA in ‌2011 and 2013‌. Twelve years later, the company has three separate stands at the IAA, marking its commitment to international expansion, and its dedication to delivering ‌tailored products and services‌ to global users.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

AVATR Defines New Luxury, CHANGAN DEEPAL Showcases Futuristic Design

By
Advertorial Desk
-

MUNICH, GERMANY – Media OutReach Newswire – 9 September 2025 – At ‌IAA Mobility 2025‌ in Munich, Germany, AVATR and CHANGAN DEEPAL‌ stood out as highlights of the show, drawing strong interest from visitors and media.

At the AVATR stage located on ‌Königsplatz, the ‌AVATR VISION XPECTRA concept car‌ – fresh from its global debut – took center stage alongside the brand’s full vehicle lineup. It showcased AVATR’s “Emotive Luxury” design philosophy and cutting-edge technology, guided by the aesthetic vision of award-winning designer ‌Nader Faghihzadeh‌.

AVATR currently offers four models: ‌AVATR 11, AVATR 12, AVATR 07, and AVATR 06‌. It holds nearly ‌10% of the UAE’s luxury EV market, ‌has become ‌Thailand’s highly recognized luxury EV brand‌, and earned widespread acclaim in ‌Singapore‌ just weeks after its launch. AVATR’s global community now reaches nearly 190,000 owners.

Coinciding with the European debut of the CHANGAN DEEPAL S05, Changan simultaneously unveiled its latest models in Chongqing, China: the ‌L06‌ and the S09 six-seat long-range version. This strategic parallel launch underscores Changan’s global ambitions.

CHANGAN DEEPAL’s bold, futuristic design language redefines electric aesthetics. Having already entered over seventy markets‌ across Europe, Eurasia, Southeast Asia, the Middle East, Africa, and Latin America, it will next introduce the CHANGAN DEEPAL S07 in the UK‌.

To deliver locally tailored products and services, ‌Changan Automobile‌ is investing in ‌local design, engineering, talent, and partnerships‌. It has established ‌self-operated import subsidiaries in Germany, the Netherlands, and UK‌‌. In other European markets, Changan collaborates with regional importers like ‌Autohellas (Greece), Motorgruppen (Norway), Auto-Industrial Group (Portugal), and OMR (Western Balkans)‌, and is actively expanding its network.

Europe remains a cornerstone in Changan’s global strategy, guided by its ‌”In Europe, for Europe”‌ ethos. Moving forward, Changan will accelerate its localization strategy in Europe, committing to long-term growth and deep local integration to deliver premium products and services to European users.

Hashtag: #CHANGAN

The issuer is solely responsible for the content of this announcement.

1...2,4972,4982,499...6,480Page 2,498 of 6,480